These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 32380083

  • 1. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
    Su K, Li Z, Yu Y, Zhang X.
    Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
    [Abstract] [Full Text] [Related]

  • 2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB.
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [Abstract] [Full Text] [Related]

  • 3. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [Abstract] [Full Text] [Related]

  • 4. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS, Haase VH.
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [Abstract] [Full Text] [Related]

  • 5. [HIF-ɑ: New Target For Treatment of Renal Anemia. Molecular Aspects and Activation of Pathway HREs].
    Mazza F, Cicciarelli A, Rubino F, Apponi F, Cioffi EA, Simonelli R.
    G Ital Nefrol; 2024 Jun 28; 41(3):. PubMed ID: 38943324
    [Abstract] [Full Text] [Related]

  • 6. Roxadustat: First Global Approval.
    Dhillon S.
    Drugs; 2019 Apr 28; 79(5):563-572. PubMed ID: 30805897
    [Abstract] [Full Text] [Related]

  • 7. The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1+ Cells.
    Jatho A, Zieseniss A, Brechtel-Curth K, Guo J, Böker KO, Salinas G, Wenger RH, Katschinski DM.
    Cells; 2022 Feb 21; 11(4):. PubMed ID: 35203399
    [Abstract] [Full Text] [Related]

  • 8. Effects of Roxadustat on Erythropoietin Production in the Rat Body.
    Yasuoka Y, Izumi Y, Fukuyama T, Omiya H, Pham TD, Inoue H, Oshima T, Yamazaki T, Uematsu T, Kobayashi N, Shimada Y, Nagaba Y, Yamashita T, Mukoyama M, Sato Y, Wall SM, Sands JM, Takahashi N, Kawahara K, Nonoguchi H.
    Molecules; 2022 Feb 08; 27(3):. PubMed ID: 35164384
    [Abstract] [Full Text] [Related]

  • 9. A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.
    Locatelli F, Ravera M, Esposito C, Grandaliano G, Gesualdo L, Minutolo R.
    J Nephrol; 2024 May 08; 37(4):1107-1119. PubMed ID: 38189866
    [Abstract] [Full Text] [Related]

  • 10. Stabilizing HIF to Ameliorate Anemia.
    Voit RA, Sankaran VG.
    Cell; 2020 Jan 09; 180(1):6. PubMed ID: 31951520
    [Abstract] [Full Text] [Related]

  • 11. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness.
    Liu J, Li S, Yang F, Li T, Li R, Waheed Y, Meng C, Li S, Liu K, Tong Y, Xu H, Tian C, Zhou X.
    Korean J Intern Med; 2024 May 09; 39(3):488-500. PubMed ID: 38649158
    [Abstract] [Full Text] [Related]

  • 12. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
    Haase VH.
    Hemodial Int; 2017 Jun 09; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
    [Abstract] [Full Text] [Related]

  • 13. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Groenendaal-van de Meent D, Adel MD, Noukens J, Rijnders S, Krebs-Brown A, Mateva L, Alexiev A, Schaddelee M.
    Clin Drug Investig; 2016 Sep 09; 36(9):743-751. PubMed ID: 27352308
    [Abstract] [Full Text] [Related]

  • 14. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T, Yamaguchi Y, Otsuka T, Reusch M.
    Nephron; 2020 Sep 09; 144(8):372-382. PubMed ID: 32580188
    [Abstract] [Full Text] [Related]

  • 15. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP.
    J Clin Pharmacol; 2020 Nov 09; 60(11):1432-1440. PubMed ID: 32603526
    [Abstract] [Full Text] [Related]

  • 16. Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
    Nishide S, Uchida J, Matsunaga S, Tokudome K, Yamaguchi T, Kabei K, Moriya T, Miura K, Nakatani T, Tomita S.
    J Pharmacol Sci; 2020 Jun 09; 143(2):122-126. PubMed ID: 32199747
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N, Wish JB.
    Am J Kidney Dis; 2017 Jun 09; 69(6):815-826. PubMed ID: 28242135
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and safety analysis of hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in low-risk myelodysplastic syndromes patients].
    Lyu Y, Lin ZH, Yang L, Liu H.
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar 14; 45(3):290-293. PubMed ID: 38716602
    [Abstract] [Full Text] [Related]

  • 19. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
    Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR.
    J Med Chem; 2018 Aug 23; 61(16):6964-6982. PubMed ID: 29712435
    [Abstract] [Full Text] [Related]

  • 20. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
    Schley G, Klanke B, Kalucka J, Schatz V, Daniel C, Mayer M, Goppelt-Struebe M, Herrmann M, Thorsteinsdottir M, Palsson R, Beneke A, Katschinski DM, Burzlaff N, Eckardt KU, Weidemann A, Jantsch J, Willam C.
    Kidney Int; 2019 Aug 23; 96(2):378-396. PubMed ID: 31146971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.